Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.08 – $0.17
0% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.9M | $741.9K | $10.4M | $1.5M | $4.5M | $16.5M | $40.3M | $50.8M |
| Cost of revenue | $311.0K | $485.0K | $1.4M | $980.0K | $2.5M | $11.4M | $21.6M | $28.4M |
| Gross profit | $11.6M | $234.0K | $9.0M | $539.0K | $2.0M | $5.1M | $18.7M | $22.4M |
| Gross margin | 97.4% | 31.5% | 87.0% | 35.5% | 44.7% | 30.8% | 46.4% | 44.1% |
| R&D | $4.3M | $2.5M | $3.1M | $579.0K | $1.3M | $2.5M | $2.4M | $1.6M |
| Operating income | −$5.2M | −$9.3M | −$2.2M | −$20.3M | −$41.2M | −$39.6M | −$28.6M | −$10.3M |
| EBITDA | −$2.5M | −$9.3M | $1.1M | −$23.9M | −$24.5M | −$38.3M | −$26.6M | −$9.2M |
| Net income | −$1.8M | −$9.1M | −$3.6M | −$19.7M | −$49.8M | −$42.1M | −$34.0M | −$18.0M |
| Net margin | -15.1% | -1223.9% | -34.5% | -1295.5% | -1094.5% | -254.4% | -84.5% | -35.5% |
| EPS (diluted) | -0.01 | -0.07 | -0.02 | -0.09 | -0.21 | -0.06 | -0.04 | -0.02 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $56M | $-0.00 | $-0.00–$-0.00 | 1 |
| 2027 | $75M | $0.01 | $0.00–$0.01 | 1 |
| 2028 | $85M | $0.01 | $0.01–$0.01 | 1 |
| 2029 | $127M | $0.00 | $0.00–$0.00 | 0 |
Forward consensus · source: Financial Modeling Prep
SHIELD THERAPEUTICS PLC
No one on the platform currently holds SHIEF.
No tracked institution reports a position in SHIEF as of their last filing.
No one on the platform has traded SHIEF yet.
| $94M |
| — |
| JUSHFJushi Holdings Inc. | $0.48 | +0.58% | $96M | — |
| KNTPFKintor Pharmaceutical Limited | $0.34 | +0.00% | $160M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 1.1× sales vs its 3.2× historical median P/S.
Fair value ≈ $0.22 · price $0.08 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$SHIEF Phase 3 trial w/est Apr completion date NCT05126901: https://www.clinicaltrials.gov/study/NCT05126901 Trial Tracker: https://www.fdatracker.com/trial-tracker/
View on StockTwits ↗$SHIEF Phase 3 trial w/est May completion date NCT05126901: http://clinicaltrials.gov/ct2/show/NCT05126901 Trial Tracker: https://www.fdatracker.com/trial-tracker/
View on StockTwits ↗$VTRS $SHIEF Shield therapeutics to announce yr end results for ‘22 next week, the 27 April and to provide an investor presentation. In this interview CEO Greg Maddison expresses his delight that the collaboration with Viatris is.. “of to a great start” https://youtu.be/d45VZtnJJhs
View on StockTwits ↗$SHIEF $VTRS https://www.directorstalkinterviews.com/shield-therapeutics-viatris-deal-has-the-potential-to-accelerate-sales-at-a-much-faster-rate-lonstx/4121102362
View on StockTwits ↗$VTRS $SHIEF Shield therapeutics, the UK company partnered with Viatris to break into a 2 billion dollar under-served market has announced that it will announce its final results for the year ended 31 December 2022 on Thursday 27 April 2023 and an Investor presentation. This announcement seems earlier than expected (it could have been left until end of June) and therefore implies that the bullish CEO Greg Maddison may have something to crow about, what’s good for Shield Therapeutics could also be good for Viatris Viatris deal has the potential to accelerate sales at a much faster rate If they show signs of revenue build and keep with the bullish sentiment going forward this could treble at least from this level https://*************.net/shield-therapeutics-viatris-deal-has-the-potential-to-accelerate-sales-at-a-much-faster-rate-lonstx
View on StockTwits ↗$SHIEF https://twitter.com/VOXmarkets/status/1569970769567924229?t=as60LS46Jdu4pWRrrYxWDA&s=19
View on StockTwits ↗$SHIEF https://twitter.com/HardmanandCo/status/1567766570558005248?t=-P6UKpdUI0UySnlhwk0CtA&s=19
View on StockTwits ↗$SHIEF nice recovery over the last 3 months, it is good to step back and look at the bigger picture, so used to seeing red after red day across the market even with FAANG, hopefully we a building a solid base to move higher ?,
View on StockTwits ↗$SHIEF added some more today on UK ticker STX before the inevitable Trading 212 stops buy orders, GLTA.
View on StockTwits ↗$SHIEF starting to average down, On UK ticker STX GLTA
View on StockTwits ↗$SHIEF A new ‘Vice President, Head of Marketing’.. with an impressive background joins the Shield team. https://www.linkedin.com/posts/christianacioffi_marketing-biotech-jobchange-activity-6926856420734754816-Av4_?utm_source=linkedin_share&utm_medium=ios_app
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.